Niowave, Inc.

Niowave is advancing cancer treatment by producing Actinium-225 (Ac-225) with cutting edge linear accelerator technology and radiochemistry. Our innovative approach provides reliable, scalable solutions to help accelerate the fight against cancer.

The system uses a superconducting linac instead of a nuclear reactor which is simpler to operate and less costly to license. It also eliminates the need for a nuclear reactor and weapons grade uranium (HEU).

The small batch radiochemistry operations can be automated, and do not require licensing as a nuclear reprocessing facility. Isotope production and distribution utilize existing radiopharmaceutical supply chain and FDA approval processes.